Bayer Subsidiary Gets Fast-track Status for Parkinson's Treatment in U.S.
By David Sachs
A Bayer-owned drug developer received special fast-track status from U.S. regulators for its Parkinson's disease treatment following positive phase-1 trials.
The German pharmaceutical company said Thursday that BlueRock Therapeutics' cell therapy candidate, bemdaneprocel, received the Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration.
The special status, which can speed up the treatment's delivery to market, came after a phase-1 clinical trial found the treatment was well-tolerated in patients with no major safety issues through 18 months.
"The RMAT designation for bemdaneprocel underscores the potential of this candidate to fundamentally change the way we think about Parkinson's disease care," said Christian Rommel, head of research and development at Bayer's pharmaceutical division.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
May 30, 2024 03:11 ET (07:11 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Should Emerging-Markets Stocks Stand Alone in Your Portfolio?
-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued